Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;14(2):151-174.
doi: 10.1007/s40271-020-00486-9. Epub 2020 Dec 15.

Eliciting Preferences for HIV Prevention Technologies: A Systematic Review

S Wilson Beckham  1 , Norah L Crossnohere  2   3 , Margaret Gross  4 , John F P Bridges  1   5
Affiliations

Eliciting Preferences for HIV Prevention Technologies: A Systematic Review

S Wilson Beckham et al. Patient. 2021 Mar.

Abstract

Background: Many human immunodeficiency virus (HIV) prevention technologies (pre-exposure prophylaxis, microbicides, vaccines) are available or in development. Preference elicitation methods provide insight into client preferences that may be used to optimize products and services. Given increased utilization of such methods in HIV prevention, this article identifies and reviews these methods and synthesizes their application to HIV prevention technologies.

Methods: In May 2020, we systematically searched peer-reviewed literature in PubMed, CINAHL, and Web of Science for studies employing quantitative preference elicitation methods to measure preferences for HIV prevention technologies among populations of any age, sex, or location. Quality assessment used an existing checklist (PREFS) and a novel adaptation of the Newcastle-Ottawa Scale (PROSPERO #CRD42018087027).

Results: We screened 5022 titles and abstracts, reviewed 318 full texts, and included 84 studies. Common methods employed were discrete-choice experiment (33%), conjoint analysis (25%), and willingness-to-participate/try/accept (21%). Studies were conducted in 25 countries and had a mean of 768 participants (range = 26-7176), two-thirds of them male. Common HIV prevention technologies included pre-exposure prophylaxis (23%), voluntary testing and counseling (19%), HIV self-testing (17%), vaccines (15%), and topical microbicides (9%). Most attributes focused on product design (side effects, frequency), service design (provider type, location), acceptability or willingness to accept/pay; results are summarized in these categories, by prevention type. Mean quality-adapted Newcastle-Ottawa Scale score was 4.5/8 (standard deviation = 2.1) and mean PREFS scores was 3.47/5 (standard deviation = 0.81).

Conclusions: This review synthesizes extant literature on quantitative measurement of preferences for HIV prevention technologies. This can enable practitioners to improve prevention products and interventions, and ultimately reduce HIV incidence.

PubMed Disclaimer

Conflict of interest statement

S Wilson Beckham receives research funding from Viiv Healthcare. Norah L. Crossnohere, Margaret Gross, and John F.P. Bridges have no conflicts of interests that are directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram. HIV human immunodeficiency virus, quant. pref. quantitative preference
Fig. 2
Fig. 2
Publications by year and preference elicitation method (a), and publications by year and human immunodeficiency virus prevention method (b). CV contingent valuation, PMTCT prevention of mother-to-child transmission, PreP pre-exposure prophylaxis, VMMC voluntary medical male circumcision
Fig. 3
Fig. 3
Attribute identification strategies employed, recommended by ISPOR [26]
See this image and copyright information in PMC

References

    1. Centers for Disease Control. Advancing HIV prevention: new strategies for a changing epidemic: United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(15):329–32. - PubMed
    1. Karki P, et al. The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: a systematic review. Evid Based Med Public Health. 2016;2:e1229. - PMC - PubMed
    1. Padian NS, et al. HIV prevention transformed: the new prevention research agenda. Lancet. 2011;378(9787):269–278. - PMC - PubMed
    1. Fonner VA, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–1983. - PMC - PubMed
    1. US Food and Drug Administration. FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-second-.... Accessed 13 Aug 2020.

Publication types